Full-Time

Regional Manager

Prenatal

Posted on 12/10/2024

BillionToOne

BillionToOne

501-1,000 employees

Molecular diagnostics for prenatal and oncology testing

Compensation Overview

$180k/yr

+ Commissions + Stock Options

Mid, Senior

Remote in USA

Position is remote.

Category
Field Sales
Sales & Account Management
Required Skills
Data Analysis
Requirements
  • Minimum 4+ years of field sales management experience leading a team of sales reps at a molecular diagnostics/genetics company required, specifically out of Women’s Health, Prenatal, and/or Reproductive Health selling directly to OBGYNs, MFMs, GCs, and hospitals/IDNs throughout the Great Lakes North region, with an existing portfolio of convertible client relationships
  • Strong experience hiring, developing, coaching, and motivating a team of sales reps to exceed ambitious sales goals
  • Demonstrated successful sales track record (eg. multiple award winning - President’s Club, Chairman’s Club, Circle of Excellence or equivalent), solid negotiation and closing skills, strong data analysis skills, understanding of buyer/decision maker types, exhibit effective selling, listening, presentation skills, strong focus on pull through, and good follow through skills
  • Excellent organizational and communication skills (written and verbal) with demonstrated ability to effectively present to both internal and external customers.
  • Effective time management skills required with a demonstrated ability to assess and prioritize opportunities required
  • Exceptionally bright, flexible, self-motivated and results-oriented with strong interpersonal and analytical skills and the ability to think strategically as well as execute tactically
  • Must act with a sense of urgency, with a focus on closing business
  • Ability to assess the needs of OBGYNs & MFMs and their office staff with a focus on consultative sales, coordination of logistics, and problem solving
  • Strong desire to work in a startup environment and build out a new territory and team
Responsibilities
  • Develop a comprehensive, data-driven sales strategy and business plan to build and grow market development throughout the Great Lakes North (Pittsburgh) region
  • Build and lead a team of talented, high performing sales reps in the execution of sales strategies and optimization of opportunities to increase profitability and market share
  • Recruit, Hire, Train, Manage, and Develop staff
  • Develop and enhance customized pitches to individual OBGYNs, MFMs, and prenatal Genetic Counselors
  • Use data to analyze sales results, identify industry trends, and stay abreast of competition to increase sales volume and drive success within territory

BillionToOne specializes in molecular diagnostics within the healthcare sector, focusing on prenatal screening and oncology testing. Their proprietary QCT technology allows for the detection and quantification of diseases at a single base-pair level, enabling the identification of minute variations in DNA. The company offers two main products: Northstar Select™, which helps determine the best initial therapy for patients, and Northstar Response™, which tracks the effectiveness of that therapy. Unlike many competitors, BillionToOne emphasizes accuracy and accessibility in molecular testing, providing diagnostic services directly to healthcare providers. Their goal is to enhance the efficiency and precision of molecular testing, ultimately making a positive impact on healthcare.

Company Size

501-1,000

Company Stage

Series D

Total Funding

$425.9M

Headquarters

Menlo Park, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • BillionToOne's revenue grew over 100% year-over-year, reaching $153 million in 2024.
  • The company achieved a milestone of 1 million UNITY tests, indicating strong market demand.
  • Expansion into Austin, Texas, will create 1,000 jobs, boosting operational capacity.

What critics are saying

  • Emerging competition in liquid biopsy could impact BillionToOne's market share.
  • Continuous R&D investment is needed to keep up with rapid technological advancements.
  • Dependence on UNITY test poses risk if market demand shifts or competitors advance.

What makes BillionToOne unique

  • BillionToOne's QCT technology offers single-molecule precision in DNA counting.
  • UNITY is the only prenatal test assessing fetal risk without invasive procedures.
  • Northstar products provide tailored oncology treatment and monitoring solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive pay

Retirement savings package

Parental leave

Free snacks & lunches

Medical, dental, & vision premiums

On campus perks

Free-on-site EV charging

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
PR Newswire
Apr 25th, 2025
Billiontoone To Present New Data At Aacr Annual Meeting 2025

Innovations in liquid biopsy technology demonstrate a more accurate method to infer in-tissue copy number from ctDNA, detection of a novel non-tumor derived pseudogene of GNA11, and development of an epigenetic-based method for precise tumor burden measurementMENLO PARK, Calif., April 25, 2025 /PRNewswire/ -- BillionToOne , a molecular diagnostics company with a mission to create powerful and accurate tests accessible to all, announced today several abstract presentations that will be showcased at the American Association of Cancer Research (AACR) Annual Meeting on April 25–30, 2025, in Chicago, IL.Each abstract highlights BillionToOne's relentless focus in advancing the field of liquid biopsy technology:Title: "Tumor fraction estimation and tissue copy number inference using copy number signal from a liquid biopsy assay"Session Time: 4/29/25 at 9:00 AM - 12:00 PMLocation: Poster Section 20Title: "Detection of a novel GNA11 processed pseudogene from cfDNA and implications for liquid biopsy"Session Time: 4/29/25 at 2:00 - 5:00 PMLocation: Poster Section 31Title: "Circulating cell-free methylated tumor DNA measurements correlate with plasma VAF-based tumor fraction estimates"Session Time: 4/29/25 at 2:00 - 5:00 PMLocation: Poster Section 32"These data presented at AACR represent our dedication in advancing liquid biopsy testing with our proprietary single molecule precision technology and setting new standards in what can be achieved with plasma-based tests," said Dr. Gary Palmer, Chief Medical Officer, Oncology at BillionToOne. "Together, these innovations enhance the accuracy and robustness of ctDNA-based cancer profiling and monitoring, which will ultimately enable more precise treatment decisions for patients."About BillionToOneHeadquartered in Menlo Park, California, BillionToOne is a precision diagnostics company on a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's single-molecule NGS (smNGS) platform, which includes the patented Quantitative Counting Template (QCT) technology, is the only multiplex methodology that can accurately count DNA molecules at the single-molecule level. For more information, please visit www.billiontoone.com .Media Contact: [email protected]SOURCE BillionToOne

PR Newswire
Mar 18th, 2025
Billiontoone Celebrates Major Milestone: 1 Million Unity Tests

UNITY is the only commercially available non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a single maternal blood draw.MENLO PARK, Calif., March 18, 2025 /PRNewswire/ -- BillionToOne, Inc. , a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, has reached a significant milestone of conducting one million UNITY prenatal tests. This achievement highlights the company's exceptional execution and superior product differentiation, which has fueled remarkable year-over-year growth and established BillionToOne as a leading player in the U.S. prenatal testing market.Powered by BillionToOne's patented Quantitative Counting Template™ (QCT™) molecular counting technology, the UNITY Fetal Risk Screen™ stands apart as the only prenatal genetic test that directly assesses a baby's risk for recessively inherited conditions, including cystic fibrosis, spinal muscular atrophy (SMA), and sickle cell disease, without requiring a male partner's sample or invasive testing."Surpassing 1 million UNITY tests in only 5 years is not just a milestone for our company, but a testament to how our technology is transforming prenatal care," said Oguzhan Atay, Ph.D., Co-Founder and CEO of BillionToOne. "What is more impressive is that our annual run-rate is already above 500,000 UNITY tests this year, indicating truly exponential growth and establishment of UNITY as the next standard in prenatal care. This achievement would not be possible without the dedication of our employees, the support of our partners, and the trust of our healthcare providers."BillionToOne has firmly established itself as the fastest-growing molecular diagnostics laboratory, with 100% year-over-year revenue growth in 2024.This milestone further solidifies BillionToOne's position as a leading provider in democratizing access to essential prenatal testing, particularly for those who need it most

PR Newswire
Feb 27th, 2025
Billiontoone'S Pioneering Study Demonstrates 100% Accuracy For Non-Invasive Fetal Rhd Detection In Us Population

Peer reviewed research published in Green Journal shows BillionToOne's NGS technology excels in testing diverse US populationsMENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ -- BillionToOne , a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced today the groundbreaking results from a recent large US-based clinical study demonstrating 100% accuracy in its non-invasive prenatal test (NIPT) for fetal RhD status. This is BillionToOne's third peer reviewed study of its fetal antigen assay, and the second published in The Journal of Obstetrics and Gynecology, the official journal of the American College of Obstetricians and Gynecologists (ACOG), also known as "The Green Journal," which showcases the accuracy and clinical validity of BillionToOne's fetal RhD NIPT.Approximately 15% of pregnant individuals in the US are RhD-negative. However, in ~40% of these pregnancies, the fetus is also RhD-negative, making RhoGAM administration unnecessary. To date, BillionToOne has conducted RhD testing on 469 participants through clinical validation studies, while providing over 150,000 commercial RhD tests to patients nationwide.This study demonstrates that BillionToOne's proprietary next-generation sequencing (NGS) with Quantitative Counting Template™ (QCT™) technology provides conclusive results with 100% accuracy. BillionToOne's study included all samples, including difficult to identify variants such as RHDѰ and RHD-C-DE, which are often excluded in other studies; therefore, it reflected true clinical performance

PR Newswire
Jan 28th, 2025
Billiontoone Reports Over 100% Growth In Revenue Year-Over-Year

Company Announces Record Financial Results at 43rd Annual J.P. Morgan Healthcare ConferenceMENLO PARK, Calif., Jan. 28, 2025 /PRNewswire/ -- BillionToOne , a next-generation molecular diagnostics company, announced record financial results at this year's J.P. Morgan Healthcare Conference in San Francisco. In 2024, the company's revenue reached $153 million, more than doubling from $72 million in 2023.BillionToOne's success has been driven primarily by its prenatal testing business, which has captured an estimated 15% market share in the U.S."We saw strong momentum in our prenatal business during 2024, with tremendous revenue growth and profitability in the fourth quarter," said Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne

Webrazzi
Dec 30th, 2024
2024 Yılında En Çok Yatırım Alan 10 Yerli Girişim

2021, 2022 ve 2023 yıllarında en yüksek yatırım alan yerli girişimleri sizlere aktarmıştık. Bir yılın daha sonuna gelirken, 2024 yılında en yüksek yatırımları alan yerli girişimleri derledik. Geçtiğimiz yılın en çok yatırım alan 10 yerli girişimiyle kıyaslandığında bu yıl yatırım miktarlarının yükseldiği görülmekte. Aslında 2022 yılından 2023 yılına gelindiğinde yatırım miktarlarında bir düşüş ile karşılaşılmıştı. Bu durumun 2024 yılında değiştiğini söylemek mümkün. Geçen yıl 105 milyon dolar ile listedeki en yüksek yatırımı alan Insider, bu yıl aldığı 500 milyon dolar ile çıtayı yükseltirken zirvedeki yerini korudu

INACTIVE